Pharma BD Deal Intelligence
Andrx made Watson the #3 US generics player, but a $497.8M IPR&D writedown and forced FTC divestitures blunted the near-term payoff before Watson moved on to bigger deals (Actavis 2012, Allergan 2015)
Full analysis, sources & comparables →Andrx shares rose 10.65% while Watson fell 3.06%; Standard & Poor's placed Watson on negative CreditWatch, citing concerns about Andrx's pending FDA…
The FTC challenged the deal over likely competitive harm in 13 generic drug markets and required divestitures before clearance, capping Watson's value capture.
On close, Watson became the #3 US generics company by prescriptions, with 66 pending ANDAs and a $30M annual synergy target - largely from corporate…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Generic pharma, sustained-release drug delivery; $25/share all-cash
Andrx made Watson the #3 US generics player, but a $497.8M IPR&D writedown and forced FTC divestitures blunted the near-term payoff before Watson moved on to bigger deals (Actavis 2012, Allergan 2015)
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation (this deal) | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2006 deals · Watson Pharmaceuticals (Actavis Inc.) deals